In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia

Blood

Volumn 94, Issue 8, 1999, Pages 2836-2843

  Bellosillo, Beatriz ^b   Villamor, Neus ^b   Colomer, Dolors ^b   Pons, Gabriel ^b   Montserrat, Emili ^b   Gil, Joan ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD3 ANTIGEN; CD5 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; MAFOSFAMIDE; MITOXANTRONE; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER CELL CULTURE; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG POTENTIATION; DRUG SCREENING; FEMALE; HUMAN; MALE; PRIORITY JOURNAL;

EID: 0032830965     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.8.2836.420k35_2836_2843     Document Type: Article

References (47)

1. Rozman C, Montserrat E: Chronic lymphocytic leukemia. N Engl J Med 333:1052, 1995
2. Reed JC: Molecular biology of chronic lymphocytic leukemia. Semin Oncol 25:11, 1998
3. Montserrat E, Bosch F, Rozman C: Treatment of B-cell chronic lymphocytic leukemia: Current status and future perspectives. J Intern Med Suppl 242:63, 1997
4. Keating MJ, O'Brien S, Kantarjian H, Plunkett W, Estey E, Koller C, Beran M, Freireich EJ: Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood 81:2878, 1993
5. Keating MJ, O'Brien S, Lerner S, Koller C, Beran M, Robertson LE, Freireich EJ, Estey E, Kantarjian H: Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92:1165, 1998
6. O'Brien S, Kantarjian H, Beran M, Smith T, Koller C, Estey E, Robertson LE, Lerner S, Keating M: Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 82:1695, 1993
7. Tallman MS, Hakimian D: Purine nucleoside analogs: Emerging roles in indolent lymphoproliferative disorders. Blood 86:2463, 1995
8. Cheson BD: Therapy for previously untreated chronic lymphocytic leukemia: A reevaluation. Semin Hematol 35:14, 1998 (suppl 3)
9. Rai KR, Peterson B, Elias L, Shepherd L, Hines J, Nelson D, Cheson B, Kolitz J, Schiffer CA: A randomized comparison of fludarabine and chlorambucil for patients with previously untreated chronic lymphocytic leukemia. A CALGB, SWOG, CTG/NCI-C and ECOG inter-group study. Blood 88:141a, 1996 (abstr, suppl 1)
10. French Cooperative Group on CLL, Johnson S, Smith AG, Loffler H, Osby E, Juliusson G, Emmerich B, Wyld PJ, Hiddemann W: Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, arid prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet 347:1432, 1996
11. O'Brien S: Clinical challenges in chronic lymphocytic leukemia. Semin Hematol 35:22, 1998 (suppl 3)
12. Cheson BD: Ennui or not ennui, that is the question. . . Ann Oncol 7:767, 1996
13. Adkins JC, Peters DH, Markham A: Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs 53:1005, 1997
14. O'Brien S, Kantarjian H, Beran M, Freireich E, Kornblau S, Koller C, Lerner S, Gilbreath J, Keating M: Fludarabine and cyclophosphamide therapy in chronic lymphocytic leukemia. Blood 88:480a, 1996 (abstr, suppl 1)
15. Flinn IW, Byrd JC, Seifter E, Marcellus D, Lee N, Diehl LF, Ambinder RF, Grever MR, Vogelsang G: Fludarabine and cyclophosphamide as first therapy for indolent lymphoproliferative disorders: response rates and toxicity. Blood 88:589a, 1996 (abstr, suppl 1)
16. Zaja F, Rogato A, Russo D, Marin L, Silvestri F, Baccarani M: Combined therapy with fludarabine and cyclophosphamide in relapsed/ resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas. Eur J Haematol 59:327, 1997
17. Elias L, Stock-Novack D, Head DR, Grever MR, Weick JK, Chapman RA, Godwin JE, Metz EN, Appelbaum FR: A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: A Southwest Oncology Group study. Leukemia 7:361, 1993
18. Weiss M, Spiess T, Berman E, Kempin S: Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia. Leukemia 8:1290, 1994
19. Bosch F, Perales M, Cobo F, Esteve J, Rafel M, López-Guillermo A, Ribera JM, Campo E, Montserrat E: Fludarabine, cyclophosphamide and mitoxantrone therapy in resistant or relapsed chronic lymphocytic leukemia or follicular lymphoma. Blood 90:530a, 1997 (abstr, suppl 1)
20. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P, Lesty C, Duault MT, Monconduit M, Belabbes S, Gremy F: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48:198, 1981
21. Bellosillo B, Dalmau M, Colomer D, Gil J: Involvement of CED-3/ICE proteases in the apoptosis of B-chronic lymphocytic leukemia cells. Blood 89:3378, 1997
22. Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55, 1983
23. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139:271, 1991
24. Bellosillo B, Piqué M, Barragán M, Castaño E, Villamor N, Colomer D, Montserrat E, Pons G, Gil J: Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells. Blood 92:1406, 1998
25. Goldstein H: Multilevel Statistical Models (ed 2). London, UK, Edward Arnold, 1995
26. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957, 1993
27. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88:323, 1997
28. El Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R, Newcomb EW: p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82:3452, 1993
29. Silber R, Degar B, Costin D, Newcomb EW, Mani M, Rosenberg CR, Morse L, Drygas JC, Canellakis ZN, Potmesil M: Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs. Blood 84: 3440, 1994
30. Gottardi D, De Leo AM, Alfarano A, Stacchini A, Circosta P, Gregoretti MG, Bergui L, Aragno M, Caligaris-Cappio F: Fludarabine ability to down-regulate Bcl-2 gene product in CD5+ leukaemic B cells: In vitro/in vivo correlations. Br J Haematol 99:147, 1997
31. Bromidge TJ, Turner DL, Howe DJ, Johnson SA, Rule SAJ: In vitro chemosensitivity of chronic lymphocytic leukaemia to purine analogues-correlation with clinical course. Leukemia 12:1230, 1998
32. Morabito F, Stelitano C, Callea I, Dattola A, Console G, Pucci G, Iacopino P, Callea V, DiRaimondo F, Brugiatelli M: In vitro drug-induced cytotoxicity predicts clinical response to fludarabine in B-cell chronic lymphocytic leukaemia. Br J Haematol 102:528, 1998
33. Frankfurt OS, Byrnes JJ, Seckinger D, Sugarbaker EV: Apoptosis (programmed cell death) and the evaluation of chemosensitivity in chronic lymphocytic leukemia and lymphoma. Oncol Res 5:37, 1993
34. Morabito F, Callea I, Console G, Stelitano C, Sculli G, Filangeri M, Oliva B, Musolino C, Iacopino P, Brugiatelli M: The in vitro cytotoxic effect of mitoxantrone in combination with fludarabine or pentostatin in B-cell chronic lymphocytic leukemia. Haematologica 82:560, 1997
35. Bellosillo B, Colomer D, Pons G, Gil J: Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol 100:142, 1998
36. Callea I, Console G, Sculli G, Filangeri M, Messina G, Morabito F: Chlorambucil synergizes with purine analogs in inducing in vitro cytotoxicity in B-cell chronic lymphocytic leukemia. Haematologica 83:756, 1998 (letter)
37. Brock N: Oxazaphosphorine cytostatics: Past-present-future. Seventh Cain Memorial Award lecture. Cancer Res 49:1, 1989
38. Sandoval A, Consoli U, Plunkett W: Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes. Clin Cancer Res 2:1731, 1996
39. Koehl U, Li L, Nowak B, Ruiz van Haperen V, Kornhuber B, Schwabe D, O'Brien S, Keating MJ, Plunkett W, Yang L-Y: Fludarabine and cyclophosphamide: Synergistic cytotoxicity associated with inhibition of interstrand cross-link removal. Proc Am Assoc Cancer Res 38:A10, 1997 (abstr)
40. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM, Dalla Favera R: p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88:5413, 1991
41. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux P: p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84:3148, 1994
42. Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, Stilgenbauer S: p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85:1580, 1995
43. Prives C: Signaling to p53: Breaking the MDM2-p53 circuit. Cell 95:5, 1998
44. Starostik P, Manshouri T, O'Brien S, Freireich E, Kantarjian H, Haidar M, Lerner S, Keating M, Albitar M: Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. Cancer Res 58:4552, 1998
45. Stankovic T, Weber P, Stewart G, Bedenham T, Muray J, Byrd PJ, Moss PAH, Malcolm A, Taylor R: Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukemia. Lancet 353:26, 1999
46. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S, Wang HG, Zhang X, Bullrich F, Croce CM, Rai K, Hines J, Reed JC: Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with in vitro and in vivo chemoresponses. Blood 91:3379, 1998
47. Consoli U, ElTounsi I, Sandoval A, Snell V, Kleine HD, Brown W, Robinson JR, DiRaimondo F, Plunkett W, Andreeff M: Differential induction of apoptosis by fludarabine monophosphate in leukemic B and normal T cells in chronic lymphocytic leukemia. Blood 91:1742, 1998